EMA Authorised: Buvidal (buprenorphine) — Camurus AB

View source ↗

Summary

The EMA authorised Buvidal, a long-acting buprenorphine injection for opioid use disorder, with Camurus AB as the marketing authorization holder; decision date …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Buvidal (buprenorphine)

Snippet

Status: Authorised. Therapeutic area: Opioid-Related Disorders. MAH: Camurus AB. Decision date: 21/03/2025